|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.260 USD | -59.35% |
|
-.--% | - |
| 17/12 | Sonnet BioTherapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended September 30, 2025 | CI |
| 03/12 | Top Midday Decliners | MT |
| Fiscal Period: September | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
Revenues | 5L | 3L | 1L | 18.63T | 10L | |||
Total Revenues | 5L | 3L | 1L | 18.63T | 10L | |||
Cost of Goods Sold, Total | 1.66Cr | 2.14Cr | 1.18Cr | 57.37L | 83.55L | |||
Gross Profit | -1.62Cr | -2.11Cr | -1.17Cr | -57.19L | -73.55L | |||
Selling General & Admin Expenses, Total | 89.37L | 85.75L | 71.26L | 61.31L | 84.89L | |||
R&D Expenses | - | - | - | - | - | |||
Other Operating Expenses, Total | 89.37L | 85.75L | 71.26L | 61.31L | 84.89L | |||
Operating Income | -2.51Cr | -2.97Cr | -1.88Cr | -1.18Cr | -1.58Cr | |||
Interest Expense, Total | - | - | - | - | -6L | |||
Interest And Investment Income | 15 | - | - | - | - | |||
Net Interest Expenses | 15 | - | - | - | -6L | |||
Currency Exchange Gains (Loss) | -22.04T | -52.48T | -40.08T | 84.29T | -1L | |||
Other Non Operating Income (Expenses) | - | - | - | 43.28L | 7L | |||
EBT, Excl. Unusual Items | -2.51Cr | -2.97Cr | -1.88Cr | -74.37L | -1.58Cr | |||
In Process R&D Expenses | - | - | - | - | - | |||
Other Unusual Items | 1L | - | - | - | - | |||
EBT, Incl. Unusual Items | -2.5Cr | -2.97Cr | -1.88Cr | -74.37L | -1.58Cr | |||
Income Tax Expense | - | - | - | - | 2L | |||
Earnings From Continuing Operations | -2.5Cr | -2.97Cr | -1.88Cr | -74.37L | -1.6Cr | |||
Net Income to Company | -2.5Cr | -2.97Cr | -1.88Cr | -74.37L | -1.6Cr | |||
Net Income - (IS) | -2.5Cr | -2.97Cr | -1.88Cr | -74.37L | -1.6Cr | |||
Preferred Dividend and Other Adjustments | - | - | - | - | - | |||
Net Income to Common Incl Extra Items | -2.5Cr | -2.97Cr | -1.88Cr | -74.37L | -1.6Cr | |||
Net Income to Common Excl. Extra Items | -2.5Cr | -2.97Cr | -1.88Cr | -74.37L | -1.6Cr | |||
Per Share Items | ||||||||
Net EPS - Basic | - | -1.2T | -145.12 | -11.35 | -3.92 | |||
Basic EPS - Continuing Operations | - | -1.2T | -145.12 | -11.35 | -3.92 | |||
Basic Weighted Average Shares Outstanding | - | 24.7T | 1L | 7L | 40.81L | |||
Net EPS - Diluted | - | -1.2T | -145.12 | -11.35 | -3.92 | |||
Diluted EPS - Continuing Operations | - | -1.2T | -145.12 | -11.35 | -3.92 | |||
Diluted Weighted Average Shares Outstanding | - | 24.7T | 1L | 7L | 40.81L | |||
Normalized Basic EPS | - | -751.92 | -90.7 | -7.09 | -2.42 | |||
Normalized Diluted EPS | - | -751.92 | -90.7 | -7.09 | -2.42 | |||
Supplemental Items | ||||||||
EBITDA | -2.51Cr | -2.97Cr | -1.88Cr | -1.18Cr | -1.58Cr | |||
EBITA | -2.51Cr | -2.97Cr | -1.88Cr | -1.18Cr | -1.58Cr | |||
EBIT | -2.51Cr | -2.97Cr | -1.88Cr | -1.18Cr | -1.58Cr | |||
EBITDAR | -2.5Cr | -2.96Cr | -1.87Cr | -1.17Cr | -1.57Cr | |||
Effective Tax Rate - (Ratio) | - | - | - | - | -1.38 | |||
Normalized Net Income | -1.57Cr | -1.86Cr | -1.18Cr | -46.48L | -98.71L | |||
Interest on Long-Term Debt | - | - | - | - | - | |||
Supplemental Operating Expense Items | ||||||||
General and Administrative Expenses | 89.37L | 85.75L | 71.26L | 61.31L | 84.89L | |||
Research And Development Expense From Footnotes | 1.66Cr | 2.14Cr | 1.18Cr | 57.37L | 83.55L | |||
Net Rental Expense, Total | 1L | 1L | 96.82T | 92.31T | 94.12T | |||
Imputed Operating Lease Interest Expense | - | - | - | - | 47.2L | |||
Imputed Operating Lease Depreciation | - | - | - | - | -46.26L | |||
Stock-Based Comp., COGS (Total) | 4L | 4L | 1L | 1L | 66.9T | |||
Stock-Based Comp., R&D Exp. (Total) | - | - | - | - | - | |||
Stock-Based Comp., G&A Exp. (Total) | 10L | 4L | 1L | 1L | 1L | |||
Stock-Based Comp., Other (Total) | - | - | - | - | - | |||
Total Stock-Based Compensation | 13.75L | 9L | 2L | 2L | 2L |
- Stock Market
- Stocks
- SONN Stock
- Financials Sonnet Biotherapeutics
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
















